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INTRODUCTION
Exclusion of smokers from asthma efficacy trials
In the pursuit of minimizing potential bias, randomized con-
trolled trials (RCTs) typically exclude patients with characteris-
tics that may obscure or diminish the measureable efficacy sig-
nal. The highly-selective nature of respiratory RCTs, and more 
specifically of asthma RCTs, can result in the exclusion of more 
than 95% of the general patient population.1,2 Thus, although 
registration RCTs are rigorous and provide the data necessary 
to establish the efficacy of new interventions (in idealized pa-
tients and practice conditions), they are limited in the extent to 
which their results can be extrapolated to reflect potential treat-
ment effects at the population level. 
As there are many factors that can interfere with efficacy, RCTs 
are designed with necessarily strict inclusion/exclusion criteria 
and require highly-interventional (and standardized) clinical 
management regimens.3,4 RCT patients are intensively moni-
tored throughout clinical trials to ensure complete compliance 
with the prescribed regimen, to allow measurement of different 
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markers and parameters, and to ensure early detection of pos-
sible treatment-related adverse events. In contrast, routine care 
asthma patients tend to be prescribed therapy then sent home 
in the belief (or hope) that they will follow their prescribing in-
structions and will remember how to perform the appropriate 
inhalation maneuvers. Patient – clinician interactions in routine 
care are typically driven by necessity – a need for additional 
therapy or when there is a problem to report. 
While intensive RCT clinical monitoring aims to minimize ar-
eas of potential bias, tight patient selection is also necessary. RCT 
recruitment often includes only patients with no (or negligible) 
comorbid illnesses or concurrent medications, those with good 
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inhaler technique and high adherence to study therapies; a 
clear-cut asthma diagnosis and some degree of lung function 
impairment; substantial reversibility to short-acting beta-ago-
nists and frequent rescue medication usage. Lifestyle charac-
teristics such, as cigarette smoking, typically result in patient ex-
clusion. Indeed RCT inclusion criteria around smoking are 
growing increasingly tight, often resulting in exclusion of not 
only current smokers, but also any patients with a history of 10 
pack years or more. 
The rationale for excluding smokers from asthma trials is un-
derstandable in light of the knowledge that active smoking in 
asthma is associated with worsening symptoms, accelerated 
decline in lung function, and impaired response to corticoste-
roids.3,5,6 The association between steroid resistance and ciga-
rette exposure was nicely demonstrated in a recent UK study 
designed to evaluate the association between self-report smok-
ing status (as well as rhinitis and medication adherence) and 
asthma control. A total of 3,916 patients from 85 different UK 
primary care practices completed anonymised questionnaires 
capturing validated asthma control data (the Asthma Control 
Questionnaire [ACQ]). Compared to never smokers, current 
smokers had a greater than 4-fold increase (odds ratio [OR]=  
4.33; 95% Confidence interval [CI]: 3.58-5.23; P<0.001) in risk of 
poorly-controlled asthma (ACQ >1.5). Although not as marked 
as for current smokers, ex-smokers also had significantly in-
creased odds of having poorly-controlled asthma (OR=1.59; 
95% CI: 1.36-1.87; P<0.001) compared with never smokers. 
Moreover, there was a clear relationship between the number 
of cigarettes smoked each day and asthma control (F[5,655]=  
6.08, P<0.001; Fig. 1).3
These findings were echoed in a randomized, placebo-con-
trolled study in mild asthma that compared the effect of inhaled 
fluticasone propionate (1,000 μg daily) or placebo over 3 weeks 
in 38 steroid-naive adult asthma patients (17 smokers; 21 non-
smokers). Efficacy was assessed using morning and evening 
peak expiratory flow (PEF) readings, spirometric parameters, 
bronchial hyper-reactivity, and sputum eosinophil counts. Af-
ter 3 weeks of fluticasone therapy, mean morning PEF reduced 
for current smokers while there was a significantly increase for 
non-smokers (–5 L/min vs 27 L/min, respectively). While non-
smokers receiving fluticasone experienced improvements across 
all endpoints compared with placebo, no differences in out-
comes were observed for current smokers receiving fluticasone 
therapy compared with those on placebo. These data suggest 
that in mild asthma, active cigarette smoking impairs the effica-
cy of short-term ICS treatment – an important consideration 
when managing mild asthma patients who smoke.6
Mechanisms of steroid resistance in smokers
There are a number of mechanisms and processes thought to 
contribute to the diminished response to ICS treatment seen in 
asthma patients who smoke.
Histone deacetylase 2 impairment
The molecular mechanism by which corticosteroids switch 
off the expression of inflammatory genes in diseases such as 
asthma is relatively well understood.7,8 In chronic inflammation 
pro-inflammatory transcription factors activate coordinated 
expression of multiple inflammatory genes (including cytokines, 
chemokines, adhesion molecules, and inflammatory enzymes). 
The increase in gene expression is brought about by acetylation 
of the core histones around which DNA is wound in the chro-
mosome, as a result of the intrinsic histone acetyltransferase 
activity of co-activator molecules to which these transcription 
factors bind.9 This unwinding of DNA allows RNA polymerase 
II to bind and initiate transcription that results in increased syn-
thesis of inflammatory proteins. Corticosteroids reverse the 
process by deacetylating the hyperacetylated histones through 
the recruitment of histone deacetylase 2 (HDAC2) to the acti-
vated coactivator complex.9 The process results in rewinding 
and compaction of DNA, exclusion of RNA polymerase, and 
suppression of inflammatory gene transcription. This mecha-
nism is thought to account for the anti-inflammatory effect of 
corticosteroids in asthma. Impairment of HDAC2 activity can, 
therefore, lead to a pronounced reduction in responsiveness to 
corticosteroids.
Oxidative stress
Although corticosteroid therapy has become the backbone of 
asthma management approaches, its utility in chronic obstruc-
tive pulmonary disease (COPD) is less clear. Although asthma 
and COPD both involve inflammation of the respiratory tract, 
the nature of the inflammation typically differs as COPD is nor-
mally characterized by a predominance of neutrophilic inflam-
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Fig. 1. Relationship between the number of cigarettes smoked per day and 
asthma control.3 Reproduced with permission from the Primary Care Respiratory Journal. 
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mation and high levels of oxidative stress that result in impaired 
HDAC2 activity, while asthma is usually characterized by eo-
sinophilic inflammation and lower levels of oxidative stress.10,11 
However severe8,10 and refractory asthma12 are also known to be 
characterized by increased neutrophils, and neutrophil levels 
in the sputum of asthma smokers have also been shown to be 
elevated compared to those of asthma patients with no smok-
ing history.13 An increase in neutrophils and macrophages is 
the innate immune responses to cigarette smoke-induced tis-
sue damage and the resultant increase in oxidative stress could 
account for the reduced corticosteroid responsiveness seen in 
smokers.8,14,15
Increased cysteinyl leukotrienes production
Cigarette smoking also stimulates the production of cysteinyl 
leukotrienes (CysLTs) possibly through COX-1 induction – a 
group of inflammatory mediators (leukotrienes C4, D4, and E4) 
central to asthma pathophysiology. They are associated with 
microvascular permeability and mucus hypersecretion and are 
potent smooth muscle constriction agents.16,17 Leukotriene E4 
(LTE4) is a stable end product of CysLTs metabolism in the hu-
man lung. Urine LTE4 is a reliable marker of endogenous CysLTs 
formation and can, thus, be used to monitor changes in the rate 
of CysLTs production.18 Gaki et al. conducted a study of 40 asth-
ma patients (20 smokers) to investigate whether smoking sig-
nificantly affects urine LTE4 levels. The authors found signifi-
cantly higher LTE4 levels in asthmatic smokers (164[48] pg/mg) 
compared with non-smokers (87[26.3] pg/mg; P<0.0001), 
which may suggest potential differences underlying CysLTs in-
flammatory processes in asthmatic smokers.13
Small airway remodeling
Another feature of cigarette smoking that has been implicated 
in poor response to traditional inhaled corticosteroid therapy is 
the greater presence of small airway disease in smokers. For pa-
tients with obstructive lung disease, exposure to cigarette smok-
ing is associated with infiltration of inflammatory cells into the 
small airways of the lung (typically peripheral or distal airways 
of ≤2 mm in diameter). Smoking also induces growth factor 
production in the airway walls and results greater small airway 
remodelling. The consequence of this process is a marked in-
crease in airflow resistance in the small airways and functional 
evidence of chronic airflow obstruction.15-22 If the small airways 
do play an important role in the pathogenesis of asthma in 
smokers, the limited effect of traditional ICS therapies may be 
associated with their failure to penetrate the small airways and 
address a key site of asthmatic inflammation.15
Management options
Although it is generally accepted that cigarette smoking is as-
sociated with diminished steroid response, asthma guidelines 
provide no specific management advice for smokers.23 When 
faced with a smoking asthma patient in the clinic, physicians 
must piece together the available evidence to make prudent 
and judicious prescribing decisions drawing on the limited evi-
dence available. A short review of the available data for differ-
ent asthma management approaches in smokers follows.
Smoking cessation
In terms of management, the first treatment recommendation 
for smoking asthma patients should be smoking cessation. A 
6-week asthma study showed cessation resulted in a significant 
improvement in forced expiratory volume in 1 second (FEV1) 
(P=0.040), a significant reduction in sputum neutrophils (P=  
0.039) and improvement in total cutaneous vasoconstrictor re-
sponse score to topical beclomethasone compared with con-
tinued smoking over the same period.5,24 Furthermore, in a 
study on 147 patients with asthma (66 never-smokers, 46 ex-
smokers, and 35 current smokers) replicating these clinical re-
sults, the epithelial characteristics in ex-smokers turned out to 
be similar to those in never-smokers, suggesting that the smoke-
induced tissue changes can be reversed by smoking cessation.25
However, while cessation can be advocated by the clinician, it 
is not always welcomed by the patient and there will continue to 
be substantial numbers of smoking asthma patients whose ther-
apeutic management requires additional consideration due to 
the attenuating effects of smoking on corticosteroid efficacy.
High-dose prescribing or dose escalation
Although several studies have demonstrated that cigarette 
smokers with asthma are insensitive to short-term ICS, data are 
limited on the possibilities of different ICS dosing strategies. To 
explore these issues, patients with mild asthma (n=95) were re-
cruited to a multi-centre, randomized, double-blind, parallel 
group study comparing inhaled beclomethasone dipropionate 
(BDP) at doses of 400 µg or 2,000 µg daily in smokers and non-
smokers over a longer, 12-week, period. The primary endpoint 
was the change in morning PEF. Secondary endpoints included 
evening PEF, use of reliever inhaler, number of asthma exacer-
bations, spirometric parameters, and asthma control score. Af-
ter 12 weeks of inhaled BDP therapy, there was a considerable 
difference in morning PEF of smokers compared with non-
smokers with asthma (P=0.035). Interestingly, the difference 
between smokers and non-smokers was less pronounced for 
patients in the 2,000 µg BDP arm (-15 [-50 to 21], P=0.40) com-
pared with that seen in the 400 µg BDP arm (-25 [95% CI -45 to 
24]; P=0.019) (Fig. 2). Similarly, while there was a significantly 
higher exacerbation rate among smokers compared to non-
smokers in the 400 µg BDP treatment arm (6 vs 1, respectively, 
P=0.007), no significant difference was seen in exacerbation 
rates in patients receiving the high 2,000 µg BDP daily dose (1 
vs 2, smokers vs non-smokers, respectively, P=0.661).26 These 
data build on the results of shorter-term studies showing dimin-
ished ICS efficacy in mild smoking asthmatics treated on low-
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dose ICS, by suggesting not only that diminished ICS efficacy 
holds true over a longer treatment course, but also that the dis-
parity between treatment response in smokers and non-smok-
ers appears to be reduced at higher ICS doses. Thus use of ICS 
therapy at higher dose may be a valid treatment consideration 
in patients with a current smoking status.5,26 
Leukotriene receptor antagonist therapy
Cysteinyl leukotrienes play an important role in the patho-
genesis of asthma, rhinitis (allergic and non-allergic), exercise-
induced asthma, aspirin-intolerant asthma, and virus-triggered 
asthma exacerbations. Combining this knowledge with Gaki et 
al.’s reported elevation of urine LTE4 concentration in smoking 
asthmatics compared with non-smoking asthma patients, it 
could be hypothesized that ‘targeting leukotriene’ could be a 
solution in smoking asthmatics.13,24
A large, randomized, double-blind, parallel-group study was 
recently conducted across 31 countries to evaluate the efficacy 
and safety of montelukast (10 mg once daily) and high-dose in-
haled fluticasone (250 µg twice daily) compared with placebo 
in smoking asthmatics (self-reported smoking of 0.5-2 packs a 
day).27 It was the largest asthma trial involving smokers con-
ducted to date and randomized 347, 336, and 336 patients to 
montelukast, fluticasone, and placebo, respectively. Over the 
6-month outcome period, patients in both the fluticasone and 
montelukast treatment arms demonstrated significantly more 
days of asthma control (44.97% vs 39.05%, P=0.04). Significant 
improvements on the secondary endpoint of change from 
baseline in mean daytime symptom score were observed or 
both fluticasone and montelukast compared with placebo 
(P=0.004, P=0.001, respectively); there were no significant dif-
ferences between montelukast and fluticasone (P=0.321) (Fig. 
3). However, fluticasone did significantly improve the change 
from baseline in mean morning PEF compared with placebo 
(P≤0.001) while montelukast had no significant effect (P=0.117). 
Smoking history and exposure appeared to play a role in re-
sponse to therapy – patients who had a smoking history of less 
than 11 pack years tended to show more benefit from flutica-
sone while those with a smoking history of more than 11 pack 
years tended to show greater numerical benefit with montelu-
kast. Overall, these data suggest that montelukast could be new 
treatment option to high-dose inhaled corticosteroid for asth-
ma patients who choose to continue smoking.
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in change in morning PEF (L/min) on different doses of inhaled beclomethasone. 
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Fig. 3. Smoothed spline plot of percentage of days with asthma control by treatment group versus smoking history (in pack years; A) and FEV1 percent predicted at 
baseline (B).27 Reprinted from the Journal of Allergy and Clinical Immunology, 131(3). Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, Mehta A, Strus JD, Polos PG, Philip G. 
Effect of montelukast for treatment of asthma in cigarette smokers. 2013;131(3):763-71. with permission from Elsevier.
Montelukast Fluticasone Placebo
Pe
rc
en
ta
ge
100
90
80
70
60
50
40
30
20
10
0
0 5 10 15 20 25 30
Baseline smoking history
Pe
rc
en
ta
ge
100
90
80
70
60
50
40
30
20
10
0
60 65 70 75 80 85 90
Baseline FEV1 percent predictedA B
Price et al.
Allergy Asthma Immunol Res. 2014 March;6(2):114-120. http://dx.doi.org/10.4168/aair.2014.6.2.114
Volume 6, Number 2, March 2014
118 http://e-aair.org
Extra-fine particle corticosteroid therapy
Based on the rationale that small airway abnormalities appear 
to contribute to the pathogenesis of asthma in patients who 
smoke, new ICS therapies that generate particles small enough 
to penetrate the small airways may be more effective than tra-
ditional ICS options.15
While traditional dry powder inhalers or chlorofluorocarbon-
metered dose inhalers generate particles with a median mass 
aerodynamic diameter of 2-4 μm,28 newer MDIs using hydro-
fluoroalkane (HFA) as the propellant can generate an aerosol of 
smaller particles with a median mass aerodynamic diameter of 
approximately 1 μm.29 Studies have shown that these extra-fine 
particle ICS formulations have a lung deposition rate of 50%-
60% and penetrate more deeply into the peripheral airways 
than drugs delivered via traditional inhalers.30,31 Thus, it has 
been hypothesized that targeting inflammation in both the 
central and peripheral airways may be beneficial, particularly 
for asthma phenotypes where small airways involvement is 
particularly implicated.15
This hypothesis was tested in an observational asthma study 
using clinical records pooled form the United Kingdom’s Clini-
cal Practice Research Database32 and Optimum Patient Care 
Research Database.33 The study was designed to explored the 
real-life effectiveness of extra-fine HFA BDP and standard par-
ticle size fluticasone delivered via MDI devices across patients 
of different smoking subgroups: non-smokers and in current 
and ex-smokers (combined). Using database measures of asth-
ma control and exacerbations, current/ex smokers prescribed 
extra-fine HFA-BDP had significantly lower exacerbation rates 
and significantly higher odds of achieving asthma control than 
patients prescribed fluticasone. Although exacerbation rates 
were also lower and odds of control higher among non-smok-
ers prescribed extrafine HFA-BDP compared to those receiving 
fluticasone, the difference was less marked than in the current/
ex smokers cohort.34 Although further data from studies of 
complementary study are required, these observational study 
data suggest targeting the small airways with an extra-fine for-
mulation ICS may offer benefits over traditional ICS formula-
tions in asthmatic smokers.
Combination therapy
Data are limited on the potential utility of combination thera-
py in smoking asthma patients. The long acting beta2-agonists 
formoterol and salmeterol have been shown to restore the glu-
cocorticoid-dependent transactivation suppresed by smoke in 
vitro35 and, in a short duration RCT including smoking asth-
matics, combination salmeterol/fluticasone proprionate has 
been shown to improve lung function and to reduce bronchial 
hyperresponsiveness to methacholine compared to fluticasone 
alone.36 A recent prospective observational study was carried 
out to explore the real-life effectiveness of extra-fine HFA BDP 
in combination with the long-acting beta-agonist therapy, for-
moterol (FOR) in smokers with moderate-to-severe persistent 
asthma.37 The one-year outcomes were improvement in lung 
function (measured as improvement FEV1) and improvement 
in asthma control, evaluated using the 6-question Asthma Con-
trol Questionnaire (ACQ6) and Global Initiative for Asthma 
(GINA). The effectiveness cohort comprised 568 asthma pa-
tients (123 smokers). Treatment with extra-fine HFA BDP/FOR 
via metred-dose inhaler was associated with significant (P< 
0.0001) improvements in pulmonary function (+7.1% in FEV1 
percent predicted), ACQ6 (-1.32) and GINA control (improve-
ment of control in 49.8% of patients) irrespective of smoking 
status (current, former, or ex). The study authors concluded 
that extra-fine HFA BDP/FOR is an effective management op-
tion in adult asthma patients, including smokers, treated in 
routine care.
Based on the earlier-presented data on the potential role of 
LTRA therapy in smoking asthma (and given their different 
mechanisms of action), another potentially useful treatment 
option for smoking asthmatics could be extra-fine ICS in com-
bination with LTRA therapy. However further data, from both 
real-life effectiveness studies and efficacy trials, are required.
Alternative study designs
The association between cigarette smoking and diminished 
ICS efficacy may be unequivocal and the rationale for exclud-
ing current smokers from asthma efficacy trials may be sound, 
but their exclusion has led to gaps and bias in the evidence base. 
If all patients who are unlikely to respond to a therapy are ex-
cluded from an efficacy trial, the result is an enriched popula-
tion of likely-responders and an inflated expectation of the po-
tential effect size achievable when the therapy is prescribed at 
population level. For clinicians treating asthma patients with 
known smoking habits, there remains the challenge of making 
prescribing decisions for that patient without the benefit of a 
strong evidence base for the likely effectiveness of the treatment 
options available.
In order to address the limitations of the RCT evidence base in 
this area, it is valuable to draw on (and to conduct) supplemen-
tary studies of different, complementary design. Pragmatic tri-
als and observational studies (so-called “real-life studies”) are 
often designed with much broader inclusion and exclusion cri-
teria (and less rigorous levels of patient-clinician interaction) 
than is typical of RCTs. 
Although such studies may lack the internal validity achievable 
in RCTs, they are valuable in the generalizablity of their findings 
and their ability to evaluate outcomes in patient subgroups of 
particular note, as illustrated in the aforementioned studies of ex-
tra-fine ICS (monotherapy and in combination with long-acting 
bronchodilator therapy) in smoking asthma. They can be used to 
assess clinical hypotheses and to guide and inform the design of 
RCTs to test those hypotheses in a more rigorous setting. 
The value and utility of such studies is gaining increasing rec-
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ognition among clinicians, so much so that leading respiratory 
experts have come together in 2013 to form The Respiratory 
Effectiveness Group (www.effectivenessevaluation.org) a not-
for-profit, independent, collaborative network designed to 
drive forward the field of real-life respiratory research over the 
next 5 years, advocating use of observational studies and prag-
matic trials to complement RCTs, standardizing analysis meth-
ods and setting quality benchmarks to help improve the quality 
as well as the profile of the field.
A focus of REG activities will be conducting high-quality ob-
servational studies and pragmatic trials that will help to “plug 
the gaps” in the RCT evidence base, particularly around the ef-
fectiveness of interventions in patient groups typically excluded 
from RCTs. Indeed, a recent REG-funded observational data-
base study explored differences in reliever therapy dependence 
in asthma patients across different smoking categories. A cur-
rent smoking status was associated with significantly higher mean 
daily short-acting bronchodilator usage compared to that of ex-
smokers (P<0.001) and non-smokers (P<0.001), suggesting to 
the presence of more severe asthma symptoms and greater de-
pendence on rescue medication among smokers.38
CONCLUSIONS
RCTs are crucial in establishing the efficacy of new interven-
tions and are a cornerstone of the drug licensing process, but 
they are limited in the extent to which their findings can be ex-
trapolated to the routine care environment and to the diversity 
of patients treated in everyday practice. Pragmatic trials and 
observational studies can provide complementary data to help 
inform decisions about appropriate treatment strategies in sub-
groups of patients of particular clinical interest. 
Cigarette smoking is known to diminish the efficacy of tradi-
tional ICS therapies and smoking asthma is increasingly being 
regarded as an asthma phenotype that requires recognition and 
consideration when making prescribing decisions. Drawing on 
the evidence available, asthma treatment options for smokers 
who refuse to quit may include: higher-dose prescribing (or dose 
escalation) of traditional ICS and/or use of extra-fine ICS for-
mulations to target the inflammation present in the small air-
ways; use of LTRA therapy as an alternative to traditional ICS 
therapy, and possibly also extra-fine ICS in combination with 
long-acting beta-agonist or with LTRA therapy. However, more 
studies in all of these areas are required.
 A diversity of different approaches and study designs should 
be used to further evaluate potential treatment options for smok-
ing asthma – observational studies to test hypotheses and to in-
form RCTs and pragmatic trials, and also where traditional RCTs 
are not feasible due to budget, time and/or ethical consider-
ations. Only by integrating different elements of the evidence jig-
saw can a fuller appreciation of the clinical picture be achieved 
and used to guide inform timely decision making.
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